Ascidian Therapeutics is a biotechnology company that focuses on medical and clinical gene therapy.
Ascidian Therapeutics has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in November 2023.
Ascidian Therapeutics's investors include Apple Tree Partners.
Ascidian Therapeutics is headquartered in Boston, United States.
Ascidian Therapeutics is a biotechnology company that focuses on medical and clinical gene therapy.
Ascidian Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ascidian Therapeutics — Funding & Investors." VCBacked, November 8, 2023, https://www.vcbacked.co/company/ascidian-therapeutics. Accessed September 15, 2026.
VCBacked. (2023). Ascidian Therapeutics — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/ascidian-therapeutics
{{cite web |title=Ascidian Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ascidian-therapeutics |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated